In metastatic prostate cancer, increased expression of the transient receptor potential cation channel subfamily V member 2 (TRPV2) resulted in enhanced cell motility through the invasion associated enzymes MMP9 and cathepsin B [14]. The gene discussed is TRPV2; the disease is metastatic prostate carcinoma.